Exciting Advances in Nerve-Targeted Therapies
Autonomix Medical, Inc. (NASDAQ: AMIX) is at the forefront of revolutionizing medical treatments aimed at nerve-related disorders. With a commitment to innovation, the company recently announced that its breakthrough technology and initial findings from an innovative study will be showcased at a prestigious medical conference. This event, known as the 2025 European Conference on Interventional Oncology (ECIO), will take place in Rotterdam, Netherlands, and is anticipated to gather leading experts from around the world.
Details of the Presentation at ECIO 2025
The highlight of the conference for Autonomix will be their poster presentation titled Catheter-Based Transvascular RF Neural Ablation for Severe Pancreatic Cancer Pain: First Results from The Elpis Study. This presentation will feature insights from Dr. Robert S. Schwartz, who serves as the Chief Medical Officer, and Dr. Askar Uktamovich Sabirov, the Primary Investigator at AKFA Medline Hospital. The focus of the study lies in treating severe pain due to pancreatic cancer, a condition that significantly impacts patients’ quality of life.
The Importance of the ECIO Conference
The European Conference on Interventional Oncology is renowned for being one of the most comprehensive educational platforms in the field. With over 140 lectures and 16 hands-on training sessions planned, the conference will cover a variety of topics important to interventional oncology, including advancements in immuno-oncology and improving treatment outcomes for pediatric cancer patients. This multidisciplinary approach fosters collaboration and knowledge-sharing amongst medical professionals, which is crucial for the continued advancement of treatment methods.
About Autonomix Medical, Inc.
Founded with the mission to innovate in the field of nerve-targeted medical treatments, Autonomix Medical is introducing a platform technology that involves a catheter-based microchip sensing array capable of detecting neural signals with unparalleled sensitivity. This technology is not only groundbreaking but is designed to transform the way nerve-related diseases are diagnosed and treated.
Currently focusing on severe pancreatic cancer pain management, Autonomix believes that their technology could set a new standard for care. Their approach has potential implications across multiple medical fields, including cardiology and chronic pain management. The technology remains investigational and has not yet received clearance for marketing within the United States.
Connect with Autonomix Medical
To learn more about their innovative technologies and future developments, Autonomix invites you to visit their website. They are also active on social media, connecting with audiences on platforms like X, LinkedIn, Instagram, and Facebook, where they share updates and engage with communities interested in medical advancements.
Investor and Media Contact Information
If you would like more information or wish to discuss investment opportunities with Autonomix Medical, please reach out to the JTC Team, LLC. Contact Jenene Thomas at 833-475-8247 or via email at autonomix@jtcir.com.
Frequently Asked Questions
What is Autonomix Medical, Inc. known for?
Autonomix Medical, Inc. specializes in developing innovative technologies for nerve-targeted treatments, particularly for chronic pain management.
What is the focus of the presentation at ECIO 2025?
The presentation will focus on the results of a study concerning a catheter-based treatment for severe pain caused by pancreatic cancer.
Who are the presenters at the conference?
Dr. Robert S. Schwartz and Dr. Askar Uktamovich Sabirov will present their findings at the ECIO 2025 conference.
Why is the ECIO conference significant?
The ECIO conference is a key event for professionals in interventional oncology to share knowledge, advancements, and collaborate on best practices in the field.
How can one learn more about Autonomix Medical?
Additional information can be found on the Autonomix website and through their social media channels.
